Denton economic development board backs incentives for Novartis gene‑therapy facility

The Economic Development Partnership Board voted on Nov. 25, 2025 to recommend that Denton City Council consider an incentive agreement for Novartis Gene Therapies Inc. to locate a radioligand therapy manufacturing operation at 2101 Shady Oaks in Denton.

Board members voted by voice after a staff presentation on the project and a question-and-answer period. The board’s recommendation forwards a package of local incentives — including a 50% real property tax abatement for 10 years (capped at about $2.3 million), a 50% sales tax rebate on construction materials (about $199,688), a job‑based grant (cap $300,000) and a remediation grant for $381,842 — to city council for final consideration.

Staff presenter Britney Sontelo, representing economic‑development staff, said Novartis plans a major investment and multi‑phase site remediation. “The total investment for the project is $280,000,000,” Sontelo said, with about…